Tailored to fit our multi-profile audience, the MedFIT conference programme features latest opinions on trending topics related to collaborative innovation partnerships and will focus on market access, financing and regulations. The programme is organised around three main tracks:
Track 1 – Collaborate to innovate
#medical needs, #KOLs collaborations, #hospital expectations Understanding the needs of the customers/clinicians is of outmost importance for the future development of medical technology products. Through these type of collaborations, a company can evaluate the medical need, test its product in a clinical environment and gain support from key opinion leaders. How can companies involve clinicians from the beginning of the project? What are the challenges encountered in building a transparent relationship with a KOL?
#collaboration challenges, #big players expectations, #SMEs testimonies It's increasingly clear that the medtech industry is experiencing an unprecedented level of change and bringing innovation to market may be more challenging going forward. Building collaborations to speed up innovation is not a new model, but the way the methods and timing are constructed can have a different impact on the outcome. We will debate how big players and start-ups enter into collaborations, what their expectations are and what challenges are encountered along the way?
#licensing process, #expenditure challenges, R&D best practices The industry requires new business models for joint projects, fresh ways of considering strategic investments, and innovative approaches to R&D that attract a broader spectrum of partners and open new horizons. How are these models evolving? How successful are they and how quickly can they develop? Our panelists will debate and present concrete examples of academic/industry collaborations and trans-disciplinary partnerships focusing on R&D best practices and expenditure challenges.
Track 2 – Finance and develop innovation
#soft money, #business angels, #crowdfunding Finding the right funding sources for an R&D project is not straightforward especially in this challenging environment. Regional grants and loans, trust foundations and charities, crowdfunding or business angels represents a important source of financing for innovative medtech projects. But how can companies access this money and how can companies identify the best option for their project? We will highlight the challenges related to these sources of financing and related best practices in securing these funds with our panelists?
#seed and series A, #VCs expectations, #SMEs examples
Despite existing financing options, it remains challenging to find and attract capital to finance the development of an innovation. A panel discussion will examine the perspectives of entrepreneurs and investors and discuss real life examples of financing failures and successes.
Track 3 – Market innovation
#innovative business models, #best practices, #scale up innovation
The primary aim of the two or more enterprises entering into a strategic alliance is to establish a network for sharing each other’s advantages and interests, and for using each other’s R&D. Formed to share a value chain with the aim of scaling up innovation of the enterprises involved, we will try to review in this panel what are the best practices in using strategic alliances as an entry mode to market. Our panel of experts will go back on their own path and experiences of strategic alliances, sharing perspectives to define how to create value through partnerships.
#market strategy, #reimboursement, #pricing issues Planning a market access strategy should start early in the product development process in order to increase the chances of successfully bringing an innovation to market. But how should this be done? How can a company correctly evaluate the market, pricing and reimbursement related issues? With our panel of experts, we will focus on best practices in overcoming these challenges.
#new MDR, #implementation, #impact on innovation
EU medical device legislation will change considerably and all medical devices in the current EU market will need to be recertified in the upcoming years.This new legislation imposes much stricter and more complex rules. How will this impact the medtech arena both from a European point of view and from that of foreign companies conducting business in Europe? What long term implications will the implementation of this legislation have on innovation and market investment? Which strategy should companies adopt to comply with these key requirements?
#clinical trials strategy, #major challenges, #more efficient models
Following new regulations, it is likely that there will be more medical device clinical trials. Therefore, the industry must adapt and innovate in their clinical trial design. Could the implementation of other models make clinical trials more efficient and effective? Our panelists will discuss high level strategies on how to approach regulators and which methods to apply in clinical trial design.